NASDAQ:IMNP Immune Pharmaceuticals (IMNP) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free IMNP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume12.29 million shsMarket Capitalization$8.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immune Pharmaceuticals alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Immune Pharmaceuticals Stock (NASDAQ:IMNP)Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… IMNP Stock News HeadlinesApril 23, 2024 | msn.comIncyte to acquire immune-focused drug developer EscientApril 11, 2024 | msn.comVertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says.April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, Vertex, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 2, 2024 | markets.businessinsider.comOSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of ImmunologyDecember 15, 2023 | tmcnet.comAC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b TrialDecember 15, 2023 | markets.businessinsider.comAC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b TrialApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.September 14, 2023 | benzinga.comImmune Health Supplements Market US$ 63,457.4 Million Valuation in 2033, Experiencing an Impressive CAGR of 10.4% | Future Market Insights Inc.June 8, 2023 | es-us.finanzas.yahoo.comOrgan Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market ResearchJune 6, 2023 | finanznachrichten.deTheralase Technologies Inc.: Theralase Announces Appointment of New Independent DirectorJune 6, 2023 | finance.yahoo.comTheralase(R) Announces Appointment of New Independent DirectorJune 5, 2023 | msn.comSeveral Down syndrome features may be linked to a hyperactive antiviral immune response – new researchJune 2, 2023 | finanznachrichten.deKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public OfferingJune 2, 2023 | finance.yahoo.comKiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public OfferingJune 1, 2023 | finanznachrichten.deMedexus Pharmaceuticals Inc.: Medexus to Participate in the LD Micro Invitational XIIIJune 1, 2023 | finance.yahoo.comBristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?June 1, 2023 | markets.businessinsider.comHookipa Pharma (HOOK) Gets a Buy from JMP SecuritiesMay 30, 2023 | markets.businessinsider.comPhanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical OfficerMay 29, 2023 | markets.businessinsider.comX4 Pharmaceuticals (XFOR) Gets a Buy from Stifel NicolausMay 27, 2023 | nasdaq.comHC Wainwright & Co. Reiterates Eledon Pharmaceuticals (ELDN) Buy RecommendationMay 23, 2023 | finance.yahoo.comCalciMedica Expands Executive Team with New AppointmentsMay 17, 2023 | technews.tmcnet.comBiotech Entrepreneur and Venture Capitalist Dinesh Patel Discusses Therapeutics and Medical Devices with CancerVAX CEO Ryan DaviesMay 17, 2023 | marketwatch.comMyocardial Infarction Drugs Market Size and Projection from 2023 to 2030May 17, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)May 16, 2023 | benzinga.comCAR T-Cell Therapy Market to be Worth $51.6 Billion by 2030 - Exclusive Report by Meticulous Research®See More Headlines Receive IMNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:IMNP Previous SymbolOTCMKTS:EPCT CUSIPN/A CIK1208261 Webwww.immunepharmaceuticals.com Phone201-464-2677FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares49,313,000Free FloatN/AMarket Cap$8.14 million OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Elliot M. Maza CPA (Age 62)J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director Dr. Anthony S. Fiorino (Age 51)COO & Chief Medical Officer Mr. Christine J. PetragliaDirector of Investor RelationsMs. Anna Baran-Djokovic J.D.Director of Corp. AffairsDr. Miri Ben-AmiPres of Immune Oncology Pharmaceuticals IncKey CompetitorsHepion PharmaceuticalsNASDAQ:HEPACyclerion TherapeuticsNASDAQ:CYCNVirios TherapeuticsNASDAQ:VIRIUniverse PharmaceuticalsNYSE:UPCMolecular TemplatesNASDAQ:MTEMView All Competitors IMNP Stock Analysis - Frequently Asked Questions How were Immune Pharmaceuticals' earnings last quarter? Immune Pharmaceuticals Inc (NASDAQ:IMNP) announced its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05. What other stocks do shareholders of Immune Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Pharmaceuticals investors own include Neovasc (NVCN), LadRx (CYTR), Biopharmx (BPMX), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Pernix Therapeutics (PTX), Sorrento Therapeutics (SRNE), Novavax (NVAX), DryShips (DRYS) and Heat Biologics (HTBX). This page (NASDAQ:IMNP) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
